
Nyrada Inc. Appendix 4D Half-year report
Half yearly Results and Appendix 4D
Small Caps interview with Blair Norfolk, CEO of Biome Australia Limited and Paul Hart, Canary Capital.
ReNerve Limited (ASX:RNV), a medical device company backed by Canary Capital, recently completed its initial public offering on the ASX.
ReNerve is focused on developing and marketing medical devices to enhance surgical procedures and patient outcomes in invasive nerve surgery, particularly for the repair and replacement of peripheral nerves.
Currently, there are few effective options for peripheral nerve injury (PNI) repair and the longer-term outcomes for patients are varied, often including lost functionality for the patient and related physical and mental health issues.
With an FDA-approved product, the NervAlign® Nerve Cuff, currently in market and 3 other products in development, ReNerve is in its early days of disrupting the global PNI repair industry which is anticipated to reach US$6.2Bn in 2031.
Follow the link below to learn more about ReNerve and why we believe it is an attractive investment opportunity with strong growth potential.
ReNerve Research Report & Mailing ListCanary Capital is pleased to have recently supported Aureka Limited (ASX:AKA) on its successful relisting on the ASX.
Aureka Limited (formerly Navarre Minerals) is an Australian gold exploration company with a portfolio of advanced exploration projects across Victoria. The company’s flagship project, the Stawell Corridor Irvine prospect, has a mineral resource estimate of 304 koz and an exploration target of 280-420 koz.
With an EV/Ounce of $14.6, AKA trades well below the peer median EV/Ounce of $43.9. This means the market values each ounce in Aureka’s JORC mineral resources at approximately one-third the price assigned to peers. This substantial valuation gap suggests potential for considerable upside in Aureka’s market capitalisation as it aligns more closely with its peer group.
Follow the link below to read our in-depth equity research report on Aureka Limited and feel free to join our mailing list to receive future reports.
AKA Research ReportCanary Capital offers high conviction private placements in micro and small Cap companies to Sophisticated and Experienced investors. We also offer all investors access to IPOs and general share trading services.
Learn MoreCapital raising and boutique corporate advisory services for early stage and emerging companies. We fund all business growth stages from Angel and Venture Capital to IPOs and private placements.
Learn MoreSign up and get our latest insights to help with your wealth success.
Our founders have a wealth of experience in the equity capital markets and a track record of delivering superior investor returns. The key to our outperformance is our thorough due diligence when selecting opportunities as well as our willingness to work with management to help them achieve long term success.
We are specialists in micro and small cap stocks across multiple industries. We work with a range of select brokers and institutions in all major Australian capital cities. Family offices, micro cap and small cap fund managers also directly invest in our opportunities.
We only invest in businesses which we believe are high quality emerging Australian companies. We work with management who are experienced leaders in their field and have a track record of delivering value for shareholders. Once funded, we monitor these businesses and work with them to help ensure they stay on course.
Half yearly Results and Appendix 4D
Highlights: •Development of lead drug candidate NYR-BI03 continues: -Preclinical efficacy study demonstrated 86% cardioprotective effect following myocardial ischemia-reperfusion injury. -Phase… Read more
TANDARRA GOLD PROJECT JV (BENDIGO ZONE) Six-hole diamond drilling program: Follow up at Lawry prospect. Objective: Step out… Read more